Paul N. Durrington

Active 1976–2026

Also published as
Paul N Durrington
113
Papers
32,449
Citations
83
h-index
112
i10-index

Citations

Citations per year for Paul N. Durrington1964: 2 citations1972: 1 citations1977: 1 citations1978: 2 citations1979: 7 citations1980: 2 citations1982: 1 citations1983: 4 citations1984: 5 citations1985: 3 citations1986: 3 citations1987: 5 citations1988: 7 citations1989: 10 citations1990: 14 citations1991: 17 citations1992: 24 citations1993: 22 citations1994: 29 citations1995: 45 citations1996: 30 citations1997: 71 citations1998: 127 citations1999: 88 citations2000: 128 citations2001: 143 citations2002: 153 citations2003: 235 citations2004: 240 citations2005: 192 citations2006: 251 citations2007: 192 citations2008: 222 citations2009: 241 citations2010: 177 citations2011: 250 citations2012: 263 citations2013: 321 citations2014: 309 citations2015: 335 citations2016: 306 citations2017: 215 citations2018: 159 citations2019: 619 citations2020: 534 citations2021: 452 citations2022: 380 citations2023: 314 citations2024: 412 citations2025: 177 citations2026: 25 citations1965–1971: no citations, so these years are not shown1973–1976: no citations, so these years are not shown1981: no citations, so this year is not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,057 citing papers, 19.5% of this breakdownUnited Kingdom: 1,129 citing papers, 10.7% of this breakdownItaly: 548 citing papers, 5.2% of this breakdownChina: 458 citing papers, 4.3% of this breakdownCanada: 434 citing papers, 4.1% of this breakdownNetherlands: 405 citing papers, 3.8% of this breakdownAustralia: 403 citing papers, 3.8% of this breakdownFrance: 393 citing papers, 3.7% of this breakdownGermany: 391 citing papers, 3.7% of this breakdownSpain: 337 citing papers, 3.2% of this breakdownSweden: 274 citing papers, 2.6% of this breakdownJapan: 203 citing papers, 1.9% of this breakdown
0%19.5%Other 33.5%

Fields

  • Medicine67.8%
  • Biochemistry, Genetics and Molecular Biology22.3%
  • Nursing3.3%
  • Immunology and Microbiology1.5%
  • Agricultural and Biological Sciences1%
  • Health Professions0.7%
  • Other3.4%

Topics

  • Lipoproteins and Cardiovascular Health11.1%
  • Diabetes, Cardiovascular Risks, and Lipoproteins8.9%
  • Paraoxonase enzyme and polymorphisms3.4%
  • Cancer, Lipids, and Metabolism2.9%
  • Atherosclerosis and Cardiovascular Diseases1.7%
  • Diabetes Treatment and Management1.7%
  • Other70.3%

Coauthors

All papers

Open in search
  1. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Heather Halls, Charlie Harper, C. Hawkins, William G. Herrington, G. A. Hitman, Hallvard Holdaas, Lisa Holland, Alan G. Jardine, J. Wouter Jukema, John J.P. Kastelein, Sharon Kean, Anthony Keech, Adrienne Kirby, John Kjekshus, Genell L. Knatterud, Robert H. Knopp, Wolfgang Köenig, Michael J. Koren, Vera Krane, Martin Landray, John C. LaRosa, Eva Lonn, Peter W. Macfarlane, Stephen MacMahon, Aldo P. Maggioni, Roberto Marchioli, Ian C. Marschner, Borislava Mihaylova, Lemuel A. Moyé, Sabina A. Murphy, Haruo Nakamura, Andrew Neil, Connie B. Newman, Rachel O’Connell, Chris J. Packard, Sarah Parish, Terje Pedersen, Richard Peto, Marc A. Pfeffer, Neil Poulter, David Preiss, Christina Reith, Paul M. Ridker, Michele Robertson, Frank M. Sacks, Naveed Sattar, Roland E. Schmieder, Patrick W. Serruys, Peter Sever, John Shaw, Charles L. Shear, John Simes, Peter Sleight, Enti Spata, Luigi Tavazzi, Jonathan A. Tobert, Gianni Tognoni, Andrew Tonkin, Stella Trompet, George Varigos, Christoph Wanner, Hans Wedel, Harvey D. White, John Wikstrand, Lars Wilhelmsen, Kate Wilson, Robin Young, Salim Yusuf, Faı̈ez Zannad - The Lancet 2019 cited by 791

  2. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial

    Authors: , , , , , , , , , - The Lancet 2004 cited by 3,791

  3. Effect of statin therapy on muscle symptoms: an individual participant data meta-analysis of large-scale, randomised, double-blind trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael Clearfield, Stuart M. Cobbe, Helen M. Colhoun, Björn Dahlöf, Barry R. Davis, James A. de Lemos, John R. Downs, Paul N. Durrington, Bengt Fellström, Ian Ford, Maria Grazia Franzosi, John A. Fuller, Curt D. Furberg, Robert J. Glynn, David Gordon, Antonio M. Gotto, Richard H. Grimm, Ajay Gupta, C. Hawkins, G. A. Hitman, Hallvard Holdaas, Alan G. Jardine, J. Wouter Jukema, John J.P. Kastelein, Sharon Kean, John Kjekshus, Genell L. Knatterud, Robert H. Knopp, Wolfgang Köenig, Michael J. Koren, Vera Krane, Martin Landray, John C. LaRosa, Roberto Latini, Eva Lonn, Donata Lucci, Jean MacFadyen, Peter W. Macfarlane, Stephen MacMahon, Aldo P. Maggioni, Roberto Marchioli, Ian C. Marschner, Lemuel A. Moyé, Sabina A. Murphy, Andrew Neil, Enrico Nicolis, Chris J. Packard, Sarah Parish, Terje R. Pedersen, Richard Peto, Marc A. Pfeffer, Neil R Poulter, Sara Pressel, Jeffrey L. Probstfield, Mahboob Rahman, Paul M. Ridker, Michele Robertson, Frank M. Sacks, Naveed Sattar, Roland E. Schmieder, Patrick W. Serruys, Peter Sever, John Shaw, James Shepherd, Lara M. Simpson, Peter Sleight, Luigi Tavazzi, Gianni Tognoni, Andrew Tonkin, Stella Trompet and 28 more - The Lancet 2022 cited by 246

  4. Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Stella Trompet, Harvey D. White, Salim Yusuf, Jane Armitage, Anthony Keech, John Simes, Rory Collins, Colin Baigent, Elizabeth H Barnes, Jordan Fulcher, William G. Herrington, Adrienne Kirby, Rachel O’Connell, Pierre Amarenco, Hiroyuki Arashi, Philip J. Barter, D. J. Betteridge, Michael A. Blazing, Gerard J Blauw, Jackie Bosch, Louise Bowman, Eugene Braunwald, Richard Bulbulia, Robert Byington, Michael Clearfield, Stuart M. Cobbe, Björn Dahlöf, Barry R. Davis, James A. de Lemos, John R. Downs, Bengt Fellström, Marcus Flather, Ian Ford, Maria Grazia Franzosi, John A. Fuller, Curt D. Furberg, Robert J. Glynn, Uri Goldbourt, David Gordon, Antonio M. Gotto, Richard Grimm, A Gupta, C. Hawkins, Richard Haynes, Hallvard Holdaas, Jemma C. Hopewell, Alan G. Jardine, John J.P. Kastelein, Sharon Kean, Patricia M. Kearney, George D. Kitas, John Kjekshus, Genell L. Knatterud, Robert H. Knopp, Michael J. Koren, Vera Krane, Martin Landray, John C. LaRosa, Roberto Latini, Eva Lonn, Donata Lucci, Jean MacFadyen, Peter W. Macfarlane, Stephen MacMahon, Aldo P. Maggioni, Roberto Marchioli, Lemuel A. Moyé, Sabina A. Murphy, Andrew Neil, Enrico Nicolis and 32 more - The Lancet Diabetes & Endocrinology 2024 cited by 137

  5. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , R. Hobbs, Arno W. Hoes, Patricia M. Kearney, Juhani Knuuti, Philippe Kolh, T. McDonagh, Bruno Moulin, D Poldermans, Bogdan A. Popescu, Željko Reiner, Udo Sechtem, P. A. Sirnes, Michał Tendera, Adam Torbicki, P. Vardas, P. Widimsky, Stephan Windecker, Document Reviewers, Christian Funck‐Brentano, D Poldermans, G. Berkenboom, Jacqueline de Graaf, Olivier Descamps, Nina Gotcheva, K. Griffith, Giuseppe Guida, S. Gulec, Y Henkin, Kurt Huber, Y. Antero Kesäniemi, J. Lekakis, Athanasios Manolis, Pedro Marques‐Vidal, L. Masana, John J.V. McMurray, Eugénia Mendes, Zurab Pagava, Terje Pedersen, Eva Prescott, Quitéria Rato, Giuseppe Rosano, Susana Sans, A. Stalenhoef, Lâle Tokgözoğlu, Margus Viigimaa, M. E. Wittekoek, José Luis Zamorano - European Heart Journal 2011 cited by 3,547

  6. European guidelines on cardiovascular disease prevention in clinical practice: executive summary: Fourth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (Constituted by representatives of nine societies and by invited experts)

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , A. Dudina, Alec Vahanian, A. John Camm, R. De Caterina, V. Dean, Kenneth Dickstein, Christian Funck‐Brentano, G. Filippatos, Irene Hellemans, S. D. Kristensen, Keith McGregor, U Sechtem, Sigmund Silber, Michał Tendera, P. Widimsky, José Luis Zamorano, Document reviewers:, Irene Hellemans, Attila Altiner, Enzo Bonora, Paul N. Durrington, R. Fagard, Simona Giampaoli, Harry Hemingway, Jan Håkansson, Sverre E. Kjeldsen, M. Lytken Larsen, G. Mancia, Athanasios Manolis, Kristina Orth‐Gomér, Terje Pedersen, Mike Rayner, L Rydén, Mario R. Sammut, Neil Schneiderman, Anton F. H. Stalenhoef, Lâle Tokgözoğlu, Olov Wiklund, Antonis Zampelas - European Heart Journal 2007 cited by 3,758

  7. Association of LDL Cholesterol, Non–HDL Cholesterol, and Apolipoprotein B Levels With Risk of Cardiovascular Events Among Patients Treated With Statins

    Authors: , , , , , , , , , , , , , , , , , , - JAMA 2012 cited by 798

  8. Antioxidant properties of HDL

    Authors: , , - Frontiers in Pharmacology 2015 cited by 185

  9. Improvements in Diabetic Neuropathy and Nephropathy After Bariatric Surgery: a Prospective Cohort Study

    Authors: , , , , , , , , , , , , , , , , , , - Obesity Surgery 2020 cited by 77

  10. Paraoxonase 1 and atherosclerosis

    Authors: , , - Frontiers in Cardiovascular Medicine 2023 cited by 69

  11. Severe Hypertriglyceridaemia and Chylomicronaemia Syndrome—Causes, Clinical Presentation, and Therapeutic Options

    Authors: , , , , , , , , , , , , , , , , - Metabolites 2023 cited by 40

  12. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Alice Stanton, Denis C. Shields, Eoin OʼBrien, Sue Shaw‐Hawkins, Yu Chen, Deborah A. Nickerson, Joshua D. Smith, Marie‐Pierre Dubé, S. Matthijs Boekholdt, G. Kees Hovingh, John J.P. Kastelein, Paul McKeigue, John Betteridge, Andrew Neil, Paul N. Durrington, Alex S. F. Doney, Fiona Carr, Andrew P. Morris, Mark I. McCarthy, Leif Groop, Emma Ahlqvist, Joshua C. Bis, Kenneth Rice, Nicholas L. Smith, Thomas Lumley, Eric A. Whitsel, Til Stürmer‎, Eric Boerwinkle, Julius S. Ngwa, Christopher J. O’Donnell, Ramachandran S. Vasan, Wei‐Qi Wei, Russell A. Wilke, Ching‐Ti Liu, Fangui Sun, Xiuqing Guo, Susan R. Heckbert, Wendy S. Post, Nona Sotoodehnia, Alice M. Arnold, Jeanette M. Stafford, Jingzhong Ding, David M. Herrington, Stephen B. Kritchevsky, Guðný Eiríksdóttir, Leonore J. Launer, Tamara B. Harris, Audrey Y. Chu, Franco Giulianini, Jean MacFadyen, Bryan J. Barratt, Fredrik Nyberg, Bruno H. Stricker, André G. Uitterlinden, Albert Hofman, Fernando Rivadeneira, Valur Emilsson, Oscar H. Franco, Paul M. Ridker, Vilmundur Guðnason, Ching‐Ti Liu, Joshua C. Denny, Christie M. Ballantyne, Jerome I. Rotter, L. Adrienne Cupples, Bruce M. Psaty, Colin N. A. Palmer, Jean‐Claude Tardif, Helen M. Colhoun, G. A. Hitman and 64 more - Nature Communications 2014 cited by 279

  13. Ezetimibe monotherapy for cholesterol lowering in 2,722 people: systematic review and meta‐analysis of randomized controlled trials

    Authors: , , , , , , , - Journal of Internal Medicine 2008 cited by 227

  14. Levels and Changes of HDL Cholesterol and Apolipoprotein A-I in Relation to Risk of Cardiovascular Events Among Statin-Treated Patients

    Authors: , , , , , , , , , , , , , , , , , , , , - Circulation 2013 cited by 194

  15. Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein

    Authors: , , - FEBS Letters 1991 cited by 978

  16. Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis

    Authors: , , , , , , , , , , , , , , , , - Journal of Clinical Investigation 2009 cited by 338

  17. Bariatric surgery leads to an improvement in small nerve fibre damage in subjects with obesity

    Authors: , , , , , , , , , , , , , , , , , - International Journal of Obesity 2021 cited by 51

  18. Sex differences in cardiovascular morbidity associated with familial hypercholesterolaemia: A retrospective cohort study of the UK Simon Broome register linked to national hospital records

    Authors: , , , , , , , , , , - Atherosclerosis 2020 cited by 42

  19. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study

    Authors: , , , , , , , , - European Heart Journal 2008 cited by 424

  20. Glycation as an atherogenic modification of LDL

    Authors: , , , , , - Current Opinion in Lipidology 2008 cited by 95

  21. Beyond LDL-C: unravelling the residual atherosclerotic cardiovascular disease risk landscape—focus on hypertriglyceridaemia

    Authors: , , , , , , , , , , - Frontiers in Cardiovascular Medicine 2024 cited by 30

  22. Effects of Atorvastatin on Kidney Outcomes and Cardiovascular Disease in Patients With Diabetes: An Analysis From the Collaborative Atorvastatin Diabetes Study (CARDS)

    Authors: , , , , , , , , - American Journal of Kidney Diseases 2009 cited by 254

  23. Coronary heart disease mortality in treated familial hypercholesterolaemia: Update of the UK Simon Broome FH register

    Authors: , , , , , , , , - Atherosclerosis 2018 cited by 96

  24. Targets of Statin Therapy: LDL Cholesterol, Non-HDL Cholesterol, and Apolipoprotein B in Type 2 Diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS)

    Authors: , , , , , , , , , , , - Clinical Chemistry 2009 cited by 93